The global oligonucleotide therapeutics market is projected to reach $17.7 billion by 2030, reflecting rapid expansion driven by advances in RNA based medicines, led by firms such as Alnylam Pharmaceuticals, Inc.
The report estimates the market was valued at $5.92 billion in 2024 and grew to $7.19 billion in 2025, with a projected compound annual growth rate of 19.7 percent between 2025 and 2030. The growth is linked to increasing clinical acceptance of therapies that target RNA, including antisense oligonucleotides and small interfering RNA treatments, according to the research firm.
The analysis states that improvements in delivery technologies, such as GalNAc conjugates and lipid nanoparticle systems, are supporting broader therapeutic use by improving drug stability, potency and selectivity. These advances are accelerating development of next generation precision medicines targeting neurological disorders, rare diseases and other complex conditions.
Antisense oligonucleotide based drugs accounted for the largest share of the market in 2024, while North America represented the leading regional market with more than 45 percent of revenue, according to the report. Leading companies include Alnylam Pharmaceuticals, Inc., Biogen, Sarepta Therapeutics, Inc., Astellas Pharma Inc., Jazz Pharmaceuticals Plc, Nippon Shinyaku Co., Ltd., Ionis Pharmaceuticals, Inc., Azenta US Inc., Novartis AG, and others.
The study highlights continued investment in research and development and expanding clinical pipelines as key factors expected to sustain market momentum, as pharmaceutical companies increasingly pursue RNA targeting approaches to address unmet medical needs. According to the company, growing interest in precision and personalized medicine is expected to further support long term adoption of oligonucleotide therapeutics.
